Sulodexide, an old drug with recent renewed interest

Current Vascular Pharmacology

Volumn 11, Issue 3, 2013, Pages 352-353

  Andreozzi, Giuseppe Maria ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; CYTOKINE; GELATINASE B; HEPARIN COFACTOR II; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; SCATTER FACTOR; SULODEXIDE; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT; GLYCOSAMINOGLYCAN; THROMBIN;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTERY DISEASE; DRUG ACTIVITY; EDITORIAL; FIBRINOLYSIS; GLYCOCALYX; HUMAN; INFLAMMATION; ISCHEMIA; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PLEIOTROPY; PROTEIN EXPRESSION; REPERFUSION INJURY; SHEAR STRESS; VEIN DISEASE; ANTAGONISTS AND INHIBITORS; PATHOPHYSIOLOGY; VASCULAR DISEASES; DRUG ANTAGONISM; VASCULAR DISEASE;

FIBRINOLYTIC AGENTS; GLYCOSAMINOGLYCANS; HUMANS; THROMBIN; VASCULAR DISEASES;

EID: 84878630472     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161111311030009     Document Type: Editorial

References (21)

1. Cosmi B, Cini M, Legnani C, Pancani C, Calanni F, Coccheri S. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. Thromb Res 2003; 109:333-339.
2. Mauro M, Palmieri GC, Palazzini E, Barbanti M, Calanni Rindina F, Milani MR. Pharmacodynamic effects of single and repeated doses of oral sulodexide in healthy volunteers. A placebo-controlled study with an enteric-coated formulation. Curr Med Res Opin 1993; 13:87-95.
3. Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev 1998; 18: 1-20.
4. Ofosu FA. Pharmacological actions of sulodexide. Semin Thromb Hemost 1998; 24: 127-138.
5. Messa GL, La Placa G, Puccetti L, et al. Pharmacodynamic effects of sulodexide on profibrinolytic and haemorrheological patterns. Clin Drug Investig 1995; 10:165-171.
6. Andreozzi GM. Sulodexide in the Treatment of Chronic Venous Disease. Am J Cardiovasc Drugs 2012; 12: 73-81.
7. Saharay M, Shields DA, Georgiannos SN, Porter JB, Scurr JH, Coleridge Smith PD. Endothelial activation in patients with chronic venous disease. Eur J Vasc Endovasc Surg 1998;15:342-349.
8. Takase S, Bergan JJ, Schmid-Schonbein G. Expression of adhesion molecules and cytokines on saphenous veins in chronic venous insufficiency. Ann Vasc Surg 2000;14:427-435.
9. Bergan JJ, Schmid-Schonbein GW, Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Chronic venous disease. N Engl J Med 2006;355:488-498.
10. Nicolaides AN. Chronic venous disease and the leukocyte-endothelium interaction: from symptoms to ulceration. Angiology 2005;56 (Suppl 1):S11-9.
11. Lauver DA, Booth EA, White AJ, Poradosu E, Lucchesi BR. Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C- reactive protein in areas of infarction without affecting hemostasis. J Pharmacol Exp Ther 2005;312:794-800.
12. Ciszewicz M, Polubinska A, Antoniewicz A, Suminska-Jasinska K, Breborowicz A. Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. Trans Res 2009;153:118-123.
13. Karon J, Polubinska A, Antoniewicz AA, Suminska-Jasinska K, Breborowicz A: Anti-inflammatory effect of sulodexide during acute peritonitis in rats. Blood Purif 2007; 25:510-514.
14. Borawski J, Dubowski M, Pawlak K, Mysliwiec M. Sulodexide induces hepatocyte growth factor release in humans. Eur J Pharmacol 2007; 558:167-171.
15. Gozdzikiewicz J, Borawski J, Mysliwiec M. Pleiotropic effects of heparin and heparinoids in peritoneal dialysis. Clin Appl Thromb Hemost 2009;15:92-97.
16. Borawski J, Gozdzikiewicz J, Dubowski M, Pawlak K, Mysliwiec M. Tissue factor pathway inhibitor release and depletion by sulodexide in humans. Adv Med Sci 2009;54:32-36.
17. Mannello F, Raffetto JD. Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research. Am J Trans Res 2011;3:149-158.
18. Mannello F, Medda V, Ligi D, Raffetto JD. Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases. Curr Vasc Pharmacol 2013;11:368-379.
19. Lauver DA, Lucchesi BR. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev 2006;24:214-226.
20. Abaterusso C, Gambaro G. The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy. Treatments Endocrinol 2006; 5:211-222.
21. Broekhuizen LN, Lemkes BA, Mooij HL, Meuwese MC, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type2 diabetes mellitus. Diabetologia 2010; 53:46-55.